Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphosys Ag (MOR)
NASDAQ:MOR
Morphosys Ag (MOR) Stock Price & Analysis
233 Followers
MOR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.19 - $18.31
Previous Close$17.95
Volume559.27K
Average Volume (3M)1.92M
Market Cap
$2.72B
Enterprise Value$2.82B
Total Cash (Recent Filing)€158.50M
Total Debt (Recent Filing)€256.45M
Price to Earnings (P/E)-11.6
Beta0.96
Next Earnings
Apr 29, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding150,620,548
10 Day Avg. Volume392,049
30 Day Avg. Volume1,922,143
Standard Deviation0.17
R-Squared0.12
Alpha-0.00394
Financial Highlights & Ratios
Price to Book (P/B)-2.37
Price to Sales (P/S)11.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.25Price Target Upside1.67% Upside
Rating ConsensusHold
Number of Analyst Covering3
Morphosys Ag News
PremiumCompany Announcements
MorphoSys AG Unveils Cancer Drug Trial Progress
PremiumCompany Announcements
MorphoSys AG Shares Shift in Major Holdings
PremiumCompany Announcements
MorphoSys AG Reports Major Shareholding Change
PremiumCompany Announcements
Morgan Stanley Adjusts Stake in MorphoSys AGPremiumCompany Announcements
MorphoSys AG Reports Change in Major Holdings
PremiumCompany Announcements
MorphoSys AG Reports Shift in Voting Rights
PremiumCompany Announcements
MorphoSys Shareholding Shift with Barclays’ Increased Stake
PremiumCompany Announcements
MorphoSys AG Reports Major Norwegian StakeBulls Say, Bears Say
Bulls Say
Acquisition ProgressNVS' acquisition of MOR is on track to close which provides clarity to investors.
Drug EfficacyResults from Phase 3 MANIFEST-2 demonstrated clear benefits in myelofibrosis, notably in spleen size reduction.
Strategic DevelopmentMorphoSys is planning to submit for regulatory approval in the U.S. and Europe, indicating progress towards commercialization.
Bears Say
Analyst RatingThe analyst downgrades the stock to Equal Weight, suggesting limited upside potential from the current price.
Analyst RatingRating lowered to Market Perform from Market Outperform on MorphoSys.
Corporate NegotiationsThere is no certainty negotiations will conclude successfully.
---
Ownership Overview
0.00%
Insiders
3.29% Mutual Funds
0.67% Other Institutional Investors
96.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MOR FAQ
What was Morphosys Ag’s price range in the past 12 months?
Morphosys Ag lowest stock price was $4.18 and its highest was $18.30 in the past 12 months.
What is Morphosys Ag’s market cap?
Currently, no data Available
When is Morphosys Ag’s upcoming earnings report date?
Morphosys Ag’s upcoming earnings report date is Apr 29, 2024 which is in 4 days.
How were Morphosys Ag’s earnings last quarter?
Morphosys Ag released its earnings results on Mar 13, 2024. The company reported $0.389 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $0.896.
Is Morphosys Ag overvalued?
According to Wall Street analysts Morphosys Ag’s price is currently Undervalued.
Does Morphosys Ag pay dividends?
Morphosys Ag does not currently pay dividends.
What is Morphosys Ag’s EPS estimate?
Morphosys Ag’s EPS estimate is -$0.08.
How many shares outstanding does Morphosys Ag have?
Morphosys Ag has 150,865,690 shares outstanding.
What happened to Morphosys Ag’s price movement after its last earnings report?
Morphosys Ag reported an EPS of $0.389 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -0.554%.
Which hedge fund is a major shareholder of Morphosys Ag?
Among the largest hedge funds holding Morphosys Ag’s share is EntryPoint Capital, LLC. It holds Morphosys Ag’s shares valued at 228K.
---
Morphosys Ag Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.25 (1.67% Upside)
$18.25 (1.67% Upside)
Blogger Sentiment
Bullish
MOR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.53%
12-Months-Change
Fundamentals
Return on Equity
-185.77%
Trailing 12-Months
Asset Growth
-12.50%
Trailing 12-Months
Company Description
Morphosys Ag
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
---
MOR Company Deck
---
MOR Earnings Call
Q4 2024
0:00 / 0:00
---
MOR Stock 12 Months Forecast
Average Price Target
$18.25
▲(1.67% Upside)
Technical Analysis
Best Analysts Covering MOR
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+12.50%
reiterated a buy rating 5 months ago
Copying James Gordon's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.50% per trade.
---